Weight-based heparin protocol using antifactor Xa monitoring

Smith, Michael L.; Wheeler, Kathryn E.
March 2010
American Journal of Health-System Pharmacy;3/1/2010, Vol. 67 Issue 5, p371
Academic Journal
Purpose. The performance of a weight-based dosing protocol for unfractionated heparin (UFH) infusions using antifactor Xa monitoring was evaluated. Methods. The first 50 patients to receive a UFH infusion per the new protocol for over 24 hours, regardless of indication, were included in the analysis. All patients received a bolus dose of 26 units/kg, followed by an i.v. infusion of 15 units/kg/ hr based on actual body weight, with no maximum dosage. Antifactor Xa levels were measured every 6 hours after infusion initiation and after every rate change until stable, defined as two consecutive results within the target range of 0.3-0.7 unit/mL, and every 24 hours thereafter. If a level was outside of the target range, the infusion rate was adjusted. Primary outcomes measured included the percentage of patients with a target level at the first test (obtained 6 hours after the start of therapy) and within the first 24 hours. The success of the protocol in obese patients versus nonobese patients was also analyzed. Results. Of the 50 patients enrolled, 26 (52%) achieved a target antifactor Xa concentration 6 hours after infusion initiation. Only 4 patients did not have an antifactor Xa concentration in the target range within 24 hours. Of the 17 patients weighing more than 100 kg, 16 (94%) had a value within the target range within 24 hours. Conclusion. A weight-based UFH dosing nomogram using antifactor Xa monitoring resulted in a high percentage of patients achieving target antifactor Xa values within the first 24 hours of therapy.


Related Articles

  • Proteolytic Antibodies against Factor VIII in Hemophilia A. Stollar, B. David // New England Journal of Medicine;2/28/2002, Vol. 346 Issue 9, p702 

    Editorial. Focuses on inhibitory antibodies to factor VIII that arise in patients with hemophilia A who receive replacement therapy with factor VIII protein. How the antibodies complicate the treatment of hemophilia; Mentions an article in this issue by Lacroix-Desmazes and others; Description...

  • Development of inhibitors with recombinant factor VIII products.  // Reactions Weekly;10/22/2005, Issue 1074, p2 

    Reports on the development of antibodies against factor VIII inhibitors in previously treated patients for all recombinant factor VIII products according to the Committee for Medicinal Products for Human Use of the European Agency (EMEA) for the Evaluation of Medicinal Products in 2005. ...

  • Cholecystectomy and Acquired Factor VIII Inhibitor Coagulopathy.  // American Surgeon;Sep2004, Vol. 70 Issue 9, p815 

    The purpose of this study was to describe the outcome of patients undergoing surgery with recognized and unrecognized factor VIII inhibitor. The setting was a tertiary care center with a community-based general surgery training program. Two patients with acquired factor VIII inhibitor...

  • Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Taher, A.; Abiad, R.; Uthman, I. // Lupus;2003, Vol. 12 Issue 11, p854 

    Acquired haemophilia or factor VIII (FVIII) deficiency,caused by FVIII inhibitor antibodies, is avery rare condition that commonly results in severe haemorrhagic complications. We report a case of acquired haemophilia presenting with a left calf nontraumatic haematoma. The patient was also found...

  • Inhibidores adquiridos de la coagulación en una paciente con lupus eritematoso sistémico y anticuerpos antifosfolipídicos: respuesta a rituximab. Jiménez, Enrique Ortiz Jiménex; Fragoso, Sergio Loera; Gabayet, Marina Rull // Reumatologia Clinica;mar/abr2008, Vol. 4 Issue 2, p74 

    Hematologic signs of systemic lupus erythematosus are diverse (SLE). Although a delayed coagulation time is anti-phospholipid antibody related, thrombotic events are the usual clinical manifestation. Spontaneous appearance of circulating anticoagulant in the absence of a previous coagulation...

  • Acute renal failure as a complication of acquired hemophilia due to autoantibody to factor VIII. Otaki, Yasuhiro; Kouda, Ryo; Fujimura, Takeo; Nakatsue, Takeshi; Wakasugi, Minako; Murakami, Shuichi; Kuroda, Takeshi; Narita, Ichiei; Nakano, Masaaki; Gejyo, Fumitake // Clinical & Experimental Nephrology;Feb2010, Vol. 14 Issue 1, p85 

    A 53-year-old Japanese woman, without any specific medical or family history, was admitted to our hospital for acute renal failure with macrohematuria. Routine blood analysis, including blood coagulation test, revealed azotemia accompanied by prolonged activated partial thromboplastin time...

  • The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. Lacroix-Desmazes, Sébastien; Bayry, Jagadeesh; Misra, Namita; Horn, Michael P.; Villard, Sylvie; Pashov, Anastas; Stieltjes, Natalie; d'Oiron, Roseline; Saint-Remy, Jean-Marie; Hoebeke, Johan; Kazatchkine, Michel D.; Reinbolt, Joseph; Mohanty, Dipika; Kaveri, Srini V. // New England Journal of Medicine;2/28/2002, Vol. 346 Issue 9, p662 

    Background: Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII antibodies has been proposed as a mechanism of inactivation of factor VIII. Methods:...

  • Factor VIII Inhibitor Assays: Methodology, Shortcomings, and Challenges. van Geffen, M.; Dardikh, M.; Verbruggen, B. // Journal of Coagulation Disorders;2010, Vol. 2 Issue 1, p1 

    Development of inhibitory antibodies against factor VIII is a serious complication in the treatment of hemophilia patients, as these antibodies inactivate factor VIII, resulting in an increased bleeding tendency and morbidity. The clinical manifestation of inhibitors has to be analyzed by...

  • Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding --Successful thrombolysis under heparin therapy. Ettingshausen, C. Escuriola; Saguer, I. Martinez; Kreuz, W. // European Journal of Pediatrics. Supplement;1999, Vol. 158, pS180 

    We report on a 14-year-old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII. For treatment of a post-traumatic intramural jejunal haematoma with extension into the mesenterium the patient received continuous infusion (CI) of a high purity...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics